Clinical implications of estrone sulfate measurement in laboratory medicine

References

• Barnes R, Levrant S. Pharmacology of estrogen. In: Lobo R, ed. Treatment of the postmenopausal woman: Basic and clinical aspects. 3rd ed. Burlington (MA): Academic Press, 2007:767–78
   Google Scholar
• Noel CT, Reed MJ, Jacobs HS, James VH. The plasma concentration of oestrone sulphate in postmenopausal women: lack of diurnal variation, effect of ovariectomy, age and weight. J Steroid Biochem 1981;14:1101–5
   PubMedGoogle Scholar
• Jasonni M, Bulletti C, Franceschetti F, et al. Metabolic clearance rate of oestrone sulphate in post-menopausal women. Maturitas 1984;5:251–7
   PubMed Web of Science ®Google Scholar
• Pasqualini JR. Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad Sci 2009;1155:88–98
   PubMed Web of Science ®Google Scholar
• Lønning PE, Johannessen DC, Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Brit J Cancer 1989;60:107–11
   PubMed Web of Science ®Google Scholar
• Castagnetta L, Granata OM, Brignone G, et al. Steroid patterns of benign breast disease. Ann N Y Acad Sci 1990;586:121–36
   PubMed Web of Science ®Google Scholar
• Hawkins RA, Oakey RE. Estimation of oestrone sulphate, oestradiol-17beta and oestrone in peripheral plasma: concentrations during the menstrual cycle and in men. J Endocrinol 1974;60:3–17
   PubMed Web of Science ®Google Scholar
• Ruder J, Loriaux L, Lipsett M. Estrone sulfate: production rate and metabolism in man. J Clin Invest 1972;51:1020–33
   PubMed Web of Science ®Google Scholar
• Buster J. Estrogen kinetics for clinicians. In: Sciarra J, ed. Gynecology and Obstetrics. Philadelphia: JB Lippincott Company, 1992:1–16
   Google Scholar
• Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003;86:245–53
   PubMed Web of Science ®Google Scholar
• Lønning PE, Helle H, Duong NK, et al. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009;117:31–41
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer TN, Membranes and distribution. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Baltimore (MD): Wolters Kluwer Health/Lippincott William & Wilkins, 2011:73–110
   Google Scholar
• Lønning PE, Haynes BP, Straume AH, et al. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin Cancer Res 2011;17:4948–58
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460–4
   PubMed Web of Science ®Google Scholar
• Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230–6
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Deslypere JP, Paridaens R, et al. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515–25
   PubMedGoogle Scholar
• Aedo AR, Landgren BM, Diczfalusy E. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women. Maturitas 1990;12:333–43
   PubMed Web of Science ®Google Scholar
• Slater CC, Hodis HN, Mack WJ, et al. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001;8:200–3
   PubMed Web of Science ®Google Scholar
• Zimmerman H, Thebault JJ, Duvauchelle T, et al. Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women. Clin Drug Investig 2000;20:123–34
   PubMed Web of Science ®Google Scholar
• Hammond C, Blohm P. Pharmacological background of estrogen replacement therapy and continuance. In: Fraser I, Jansen R, Lobo R, Whitehead M, eds. Estrogens and Progestogens in Clinical Practice. London: Churchill Livingstone, 1998:655–66
   Google Scholar
• Blair IA. Analysis of estrogens in serum and plasma from postmenopausal women: Past present, and future. Steroids 2010;75:297–306
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011;32:81–151
   PubMed Web of Science ®Google Scholar
• Simpson E, Rubin G, Clyne C, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 2000;11:184–8
   PubMed Web of Science ®Google Scholar
• Thomas JL, Duax WL, Addlagatta A, et al. Structure/function aspects of human 3beta-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 2004;215:73–82
   PubMed Web of Science ®Google Scholar
• Adamski J, Jakob FJ. A guide to 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2001;171:1–4
   PubMed Web of Science ®Google Scholar
• Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001;45:S116–24
   PubMed Web of Science ®Google Scholar
• Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Ann Clin Biochem 2013;50:95–107
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome p450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005;227:115–24
   PubMed Web of Science ®Google Scholar
• Breitling R, Krazeisen A, Möller G, Adamski J. 17beta-hydroxysteroid dehydrogenase type 7-an ancient 3-ketosteroid reductase of cholesterogenesis. Mol Cell Endocrinol 2001;171:199–204
   PubMed Web of Science ®Google Scholar
• Jansson A. 17beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol 2009;114:64–7
   PubMed Web of Science ®Google Scholar
• Penning TM, Jin Y, Steckelbroeck S, et al. Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol Cell Endocrinol 2004;215:63–72
   PubMed Web of Science ®Google Scholar
• Lukacik P, Keller B, Bunkoczi G, et al. Structural and biochemical characterization of human orphan dhrs10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. Biochem J 2007;402:419–27
   PubMed Web of Science ®Google Scholar
• Sasano H, Suzuki T, Miki Y, Moriya T. Intracrinology of estrogens and androgens in breast carcinoma. J Steroid Biochem Mol Biol 2008;108:181–5
   PubMed Web of Science ®Google Scholar
• Shibuya R, Suzuki T, Miki Y, et al. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 2008;15:113–24
   PubMed Web of Science ®Google Scholar
• Takagi K, Moriya T, Kurosumi M, et al. Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma. Horm Cancer 2013;4:1–11
   PubMed Web of Science ®Google Scholar
• Adjei AA, Weinshilboum RM. Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 2002;292:402–8
   PubMed Web of Science ®Google Scholar
• Lindsay J, Wang LL, Li Y, Zhou SF. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008;9:99–105
   PubMed Web of Science ®Google Scholar
• Wang LQ, James MO. Sulfotransferase 2a1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate. J Steroid Biochem Mol Biol 2005;96:367–74
   PubMed Web of Science ®Google Scholar
• Nakata T, Takashima S, Shiotsu Y, et al. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J Steroid Biochem Mol Biol 2003;86:455–60
   PubMed Web of Science ®Google Scholar
• Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000;21:40–54
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270–82
   PubMed Web of Science ®Google Scholar
• Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 2001;7:273–81
   PubMed Web of Science ®Google Scholar
• Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89–96
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Wang JP. Estrogen metabolites and breast cancer. Steroids 2015;99:61–6
   PubMed Web of Science ®Google Scholar
• Endogenous Hormones and Breast Cancer Collaborative Group. Key TJ, Appleby PN, Reeves GK, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013;14:1009–19
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–16
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406–15
   PubMed Web of Science ®Google Scholar
• Farhat GN, Cummings SR, Chlebowski RT, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011;103:562–70
   PubMedGoogle Scholar
• James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res 2011;4:1626–35
   PubMed Web of Science ®Google Scholar
• Kaaks R. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071–82
   PubMed Web of Science ®Google Scholar
• Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer. Epidemiol Biomarkers Prev 2009;18:169–76
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218–26
   PubMed Web of Science ®Google Scholar
• Walker K, Bratton DJ, Frost C. Premenopausal endogenous oestrogen levels and breast cancer risk: a meta-analysis. Br J Cancer 2011;105:1451–7
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 1997;350:1047–59
   Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005;12:668–78
   PubMed Web of Science ®Google Scholar
• Chatterton J, Robert T, Geiger AS, et al. Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 2003;86:159–66
   PubMed Web of Science ®Google Scholar
• Chatterton J, Robert T, Geiger AS, et al. Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 2005;90:1686–91
   PubMed Web of Science ®Google Scholar
• Farhat GN, Parimi N, Chlebowski RT, et al. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst 2013;105:1496–503
   PubMedGoogle Scholar
• Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005;353:275–85
   PubMed Web of Science ®Google Scholar
• Silvera SAN, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res Treat 2007;110:397–409
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229–37
   PubMed Web of Science ®Google Scholar
• Zhou WB, Xue DQ, Liu XA, et al. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1053–60
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res 2014;7:211–17
   PubMed Web of Science ®Google Scholar
• Berkowitz GS, Kelsey JL, LiVolsi VA, et al. Exogenous hormone use and fibrocystic breast disease by histopathologic component. Int J Cancer 1984;34:443–9
   PubMed Web of Science ®Google Scholar
• Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999;8:123–30
   PubMed Web of Science ®Google Scholar
• Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008;100:563–71
   PubMedGoogle Scholar
• Lagiou P, Samoli E, Lagiou A, et al. A comparison of hormonal profiles between breast cancer and benign breast disease: a case-control study. Ann Oncol 2013;24:2527–33
   PubMed Web of Science ®Google Scholar
• Samoli E, Trichopoulos D, Lagiou A, et al. The hormonal profile of benign breast disease. Br J Cancer 2013;108:199–204
   PubMed Web of Science ®Google Scholar
• Audet-Walsh E, Lépine J, Grégoire J, et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab 2011;96:E330–9. doi: 10.1210/jc.2010-2050
   PubMed Web of Science ®Google Scholar
• Austin H, Austin JM, Partridge EE, et al. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991;51:568–72
   PubMed Web of Science ®Google Scholar
• Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 2015;99:8–10
   PubMed Web of Science ®Google Scholar
• Engelsen I, Akslen L, Salvesen H. Biologic markers in endometrial cancer treatment. Apmis 2009;117:693–707
   PubMed Web of Science ®Google Scholar
• Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425–32
   PubMed Web of Science ®Google Scholar
• Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127–35
   PubMed Web of Science ®Google Scholar
• Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the Eeuropean prospective investigation into cancer and nutrition (epic). Endocr Relat Cancer 2008;15:485–97
   PubMed Web of Science ®Google Scholar
• Mungenast F, Thalhammer T. Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne) 2014;5:192. doi: 10.3389/fendo.2014.00192
   PubMed Web of Science ®Google Scholar
• Bosland MC. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Lett 2013;334:28–33
   PubMed Web of Science ®Google Scholar
• Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410–16
   PubMed Web of Science ®Google Scholar
• Parsons JK. Serum testosterone and the risk of prostate cancer: Potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257–60
   PubMed Web of Science ®Google Scholar
• Severi G. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86–91
   PubMed Web of Science ®Google Scholar
• Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91:491–503
   PubMed Web of Science ®Google Scholar
• Leav I, Ho SM, Ofner P, et al. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of noble rats. J Natl Cancer Inst 1988;80:1045–53
   PubMedGoogle Scholar
• Giton F, de la Taille A, Allory Y, et al. Estrone sulfate (e1s), a prognosis marker for tumor aggressiveness in prostate cancer (pca). J Steroid Biochem Mol Biol 2008;109:158–67
   PubMed Web of Science ®Google Scholar
• Markushin Y, Gaikwad N, Zhang H, et al. Potential biomarker for early risk assessment of prostate cancer. Prostate 2006;66:1565–71
   PubMed Web of Science ®Google Scholar
• Giton F, Valleix A, Boudou P, et al. Specific radioimmunoassay of estrone sulfate. Application to measurement in male plasma. J Steroid Biochem Mol Biol 2002;81:85–94
   PubMed Web of Science ®Google Scholar
• Mendelson CR, Simpson ER. Regulation of estrogen biosynthesis by human adipose cells in vitro. Mol Cell Endocrinol 1987;52:169–76
   PubMed Web of Science ®Google Scholar
• Siiteri P, Hammond G, Nisker J. Increased availability of serum estrogens in breast cancer: a new hypothesis. In: Pike M, Siiteri P, Welsch C, eds. Banbury Report 8 Hormones and Breast Cancer. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1981:87–106
   Google Scholar
• Stocco C. Tissue physiology and pathology of aromatase. Steroids 2012;77:27–35
   PubMed Web of Science ®Google Scholar
• Bergström A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421–30
   PubMed Web of Science ®Google Scholar
• Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst 2015;107:pii. djv088. doi: 10.1093/jnci/djv088
   Google Scholar
• Jasonni VM, Bulletti C, Franceschetti F, et al. Estrone sulphate plasma levels in postmenopausal women with and without endometrial cancer. Cancer 1984;53:2698–700
   PubMed Web of Science ®Google Scholar
• Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev 2013;39:507–17
   PubMed Web of Science ®Google Scholar
• Sommeijer DW, Sjoquist KM, Friedlander M. Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. Current. Oncol Rep 2013;15:541–8
   Web of Science ®Google Scholar
• Thomas MP, Potter BVL. Estrogen o-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential. J Steroid Biochem Mol Biol 2015;153:160–9
   PubMed Web of Science ®Google Scholar
• Lønning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol 2011;22:503–14
   PubMed Web of Science ®Google Scholar
• Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 2008;14:6330–5
   PubMed Web of Science ®Google Scholar
• Lunardi G, Piccioli P, Bruzzi P, et al. Plasma estrone sulfate concentrations and genetic variation at the cyp19a1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Res Treat 2012;137:167–74
   PubMed Web of Science ®Google Scholar
• Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 2008;26:1671–6
   PubMed Web of Science ®Google Scholar
• Bighin C, Lunardi G, Del Mastro L, et al. Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors. Oncologist 2010;15:1270–2
   PubMed Web of Science ®Google Scholar
• Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 2010;21:1243–5
   PubMed Web of Science ®Google Scholar
• Mauras N, O’Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000;85:2370–7
   PubMed Web of Science ®Google Scholar
• Geisler J, Ekse D, Helle H, et al. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 2008;109:90–5
   PubMed Web of Science ®Google Scholar
• Purohit A, Foster PA. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol 2012;212:99–110
   PubMed Web of Science ®Google Scholar
• Stanway SJ. Phase i study of stx 64 (667 coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585–92
   PubMed Web of Science ®Google Scholar
• Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005;7:1–4. doi: 10.1186/bcr960
   PubMed Web of Science ®Google Scholar
• Demers LM, Hankinson SE, Haymond S, et al. Measuring estrogen exposure and metabolism: workshop recommendations on clinical issues. J Clin Endocrinol Metab 2015;100:2165–70
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Manson JE, Spiegelman D, et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4:649–54
   PubMed Web of Science ®Google Scholar
• Reinsberg J, Bätz O, Bertsch T, et al. Precision and long-term stability of different estradiol immunoassays assessed in a multi-center quality control study. Clin Lab 2009;55:201–6
   PubMed Web of Science ®Google Scholar
• Giton F, Caron P, Bérubé R, et al. Plasma estrone sulfate assay in men: comparison of radioimmunoassay, mass spectrometry coupled to gas chromatography (gc-ms), and liquid chromatography-tandem mass spectrometry (lc-ms/ms). Clin Chim Acta 2010;411:1208–13
   PubMed Web of Science ®Google Scholar
• Ranadive GN, Mistry JS, Damodaran K, et al. Rapid, convenient radioimmunoassay of estrone sulfate. Clin Chem 1998;44:244–9
   PubMed Web of Science ®Google Scholar
• Geisler J, Berntsen H, Lønning PE. A novel hplc-ria method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Mol Biol 2000;72:259–64
   PubMed Web of Science ®Google Scholar
• Labrie F, Bélanger A, Bélanger P, et al. Metabolism of dhea in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007;103:178–88
   PubMed Web of Science ®Google Scholar
• Stanway SJ, Purohit A, Reed MJ. Measurement of estrone sulfate in postmenopausal women: comparison of direct ria and gc-ms/ms methods for monitoring response to endocrine therapy in women with breast cancer. Anticancer Res 2007;27:2765–7
   PubMed Web of Science ®Google Scholar
• Rezvanpour A, Turner J, Howell M, et al. Estrone sulfate testing: evaluation of serum measurements by radioimmunoassay. Clin Biochem 2015;48:1020–1
   Web of Science ®Google Scholar
• Santner SJ, Leszczynski D, Wright C, et al. Estrone sulfate: A potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat 1986;7:35–44
   PubMed Web of Science ®Google Scholar
• Geisler J, Lønning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 2005;11:2809–21
   PubMed Web of Science ®Google Scholar
• Lønning PE, Ekse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol 1995;55:409–12
   PubMed Web of Science ®Google Scholar
• Geisler J, Lønning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 2005;95:75–81
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Guan M, Laughlin GA, et al. Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 2008;17:1674–81
   PubMed Web of Science ®Google Scholar
• Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14:169–87
   PubMed Web of Science ®Google Scholar